Sunday 18 October 2026
Export BIOLQ’s income statement to Excel — free account
Biolase, Inc.
BIOLQ Healthcare Medical Devices
Biolase, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $49.2 million, up 1.45% from fiscal 2022. Revenue growth for five consecutive years, operating cash flow growth for three.
0.00
0.00
NaN
Follow BIOLQ
| Older periods | Dec '23 | Mar '24 | Jun '24 | Sep '24 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.03 | 0.07 | 0.08 | 0.05 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(0.62) | (0.57) | (5.00) | (0.56) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.18 | 0.23 | 0.26 | 0.33 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.63) | (0.77) | (1.02) | (1.14) | |
EV/FCF |
(0.58) | (0.75) | (1.03) | (1.16) | |
Quick Ratio |
0.61 | 0.56 | 0.32 | 0.23 | |
Current Ratio |
1.26 | 1.17 | 0.71 | 0.63 | |
Net Debt/EBITDA |
(1.74) | (2.04) | (3.32) | 188.03 | |
Debt/Assets |
40.02% | 40.77% | 43.81% | 58.89% | |
Debt/Equity |
7.18 | 52.07 | (6.31) | (3.29) | |
Asset Turnover |
1.34 | 1.28 | 1.31 | 1.40 | |
Operating CF/Net income |
0.10 | 0.92 | 0.26 | 3.13 | |
Capex/Depreciation |
0.00 | 0.25 | 0.08 | 0.04 | |
Interest Coverage |
(8.42) | (7.28) | (5.49) | (1.15) | |
Research and Development Expense of Revenue |
12.24% | 12.66% | 9.27% | 8.45% | |
Selling, General and Administrative Expense of Revenue |
51.51% | 64.94% | 58.49% | 38.34% | |
Intangible Assets out of Total Assets |
0.08 | 0.09 | 0.10 | 0.11 | |
Share Based Compensation of Revenue |
1.35% | 9.31% | (0.40%) | 0.47% | |
Graham Net Nets |
(5.89) | (2.68) | (2.91) | (5.03) | |
Graham Number |
11.90 | 6.04 | 4.21 | 2.70 | |
Earnings Yield |
(2,961.82%) | (7,863.16%) | (5,536.36%) | (3,200.00%) | |
Free Cash Flow Yield |
(1,082.66%) | (434.10%) | (312.31%) | (520.19%) | |
Revenue per Share |
10.56 | 0.57 | 0.35 | 0.30 | |
Operating CF per Share |
(1.79) | (0.33) | (0.02) | (0.12) | |
Capex per Share |
0.00 | 0.01 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.79) | (0.32) | (0.02) | (0.12) | |
Cash per Share |
5.14 | 0.36 | 0.16 | 0.10 | |
Shareholders Equity per Share |
1.53 | 0.02 | (0.06) | (0.14) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.53 | 0.02 | (0.06) | (0.14) | |
Free Cash Flow |
(2.29) | (5.74) | (0.67) | (4.44) | |
Working Capital |
5.20 | 3.58 | (9.08) | (11.43) | |
Capital Expenditures |
0.00 | 0.20 | 0.06 | 0.03 | |
Net Current Asset Value |
(8.28) | (9.08) | (10.67) | (12.69) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | (0.02) | (0.01) | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
5.66 | 5.42 | 5.28 | 3.96 | |
Average Payables |
5.93 | 6.23 | 5.90 | 5.09 | |
Average Inventory |
13.66 | 14.52 | 12.12 | 11.85 | |
Average Assets |
36.64 | 38.15 | 35.14 | 32.99 | |
Average Common Equity |
2.32 | 3.11 | 1.15 | (2.45) |
Columns are period end dates